NASDAQ · NXTSHealthcarePharmaceuticals

Nexentis Technologies financials

$0.5550−2.46%
Close Nov 4, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Revenue$0.00$0.00
Gross profit$0.00$0.00
Gross margin——
Operating income-$1.7M-$8.6M
Net income-$11.1M-$6.6M
Net margin——
Diluted EPS$-13.66$-10.74
EBITDA-$1.6M-$2.2M
Operating cash flow-$539.0K-$1.4M
Free cash flow-$540.0K-$1.5M
Diluted shares0.8M0.6M

Balance sheet

Period endJun 30Mar 31
Cash & equivalents$7.6M$4.3M
Short-term investments$1.3M$1.9M
Total debt$422.0K$467.0K
Total assets$18.7M$16.4M
Total liabilities$16.5M$2.6M
Shareholders' equity$2.2M$13.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology